

# IMPLEMENTATION OF ELASTOMERIC INFUSION PUMPS FOR THE ADMINISTRATION OF ANTIMICROBIAL AGENTS IN COORDINATION WITH HOME HOSPITALITATION

Gómez-Costa E<sup>1</sup>, Feal-Cortizas MB<sup>1,2</sup>, Mateos-Salvador M<sup>1</sup>, Rotea-Salvo S<sup>1,2</sup>, Luaces-Rodríguez A<sup>1</sup>, Caeiro-Martínez L<sup>1</sup>, Fernández-Diz C<sup>1</sup>, Torres-Pérez A<sup>1</sup>, Margusino-Framiñán L<sup>1,2</sup>, Martín-Herranz MI<sup>1,2</sup>

- 1. Pharmacy Department. A Coruña University Hospital Complex (Sergas). Spain
- Research Group of Hospital Pharmacy. Biomedical Research Institute A Coruña (INIBIC)

## WHAT WAS DONE?

Implementation of a circuit for:













Preparation Elastomeric Infusion Pumps (EIPs) Hospital Pharmacy Service

Dispensing Hospital at Home (HH)

Administration Continuous Intravenous of Antimicrobial Agents Patient's House

## WHY WAS DONE?

The purpose of this initiative is to provide an effective and safe alternative for treating infections in patients who would otherwise require prolonged hospital stays.

#### The use of EIPs improves:

- Patients' quality of life.
- Reduces treatment costs by decreasing hospital admissions.

## **HOW WAS IT DONE?**



The **Pharmacy Service** contributed to the development of this initiative by:

Studying the **stability** of antimicrobial agents in the EIPs.



- Determining dilution volumes based on the maximum possible concentration.
- Assessing storage conditions.
- Selecting the appropriate EIP for each antibiotic to ensure effective and safe infusion rates.

EIPs are prepared in laminar flow hoods to maintain a sterile environment during medication preparation.



Educational materials for healthcare professionals were developed, and training sessions were conducted for HH staff.

# WHAT HAS BEEN ACHIEVED?

· 2,223 EIPs 2023 · 123 Patients



Reduction of 1,426 hospital days

Comparison to previous years:				
	2017 - 2019	2019 - 2023		
Number of Infusers	<b>↑</b> 243%	<b>↑</b> 11.9%		
Number of <b>Patients</b>	个 131%	↑ 36.7%		

The antimicrobial agents used were:				
Meropenen	59.6%	Tobramycin	1.5%	
Piperacillin/ Tazobactam	19.9%	Ampicillin	0.7%	
Cefazolin	6.8%	Acyclovir	0.6%	
Ceftazidime	5.6%	Ceftolozane/ Tazoba <i>c</i> tam	0.6%	
Ceftaroline	2.2%	Ceftriaxone	0.4%	
Penicillin G	2.1%			

### WHAT IS NEXT?

Future research is expected to expand on the efficacy and safety of this methodology by studying the stability of antimicrobial agents at different concentrations to establish a sustainable model that can benefit an increasing number of patients.

Additionally, patient surveys will be conducted to gather insights into their experiences and enhance their quality of life.

